Molden E - Search Results

1

Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015.

Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ. Baftiu A, et al. Among authors: molden e. Epilepsy Res. 2018 Jan;139:35-42. doi: 10.1016/j.eplepsyres.2017.11.001. Epub 2017 Nov 11. Epilepsy Res. 2018. PMID: 29175562

2

Serum concentrations of antidepressants in the elderly.

Waade RB, Molden E, Refsum H, Hermann M. Waade RB, et al. Among authors: molden e. Ther Drug Monit. 2012 Feb;34(1):25-30. doi: 10.1097/FTD.0b013e318241dce0. Ther Drug Monit. 2012. PMID: 22215489

3

Statin medication in patients treated with antiepileptic drugs in Norway.

Gedde-Dahl A, Devold HM, Molden E. Gedde-Dahl A, et al. Among authors: molden e. Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):881-5. doi: 10.1002/pds.3287. Epub 2012 Apr 23. Pharmacoepidemiol Drug Saf. 2012. PMID: 22529023

4

Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C. Svendsen T, et al. Among authors: molden e. Epilepsy Res. 2017 Jan;129:125-131. doi: 10.1016/j.eplepsyres.2016.12.001. Epub 2016 Dec 5. Epilepsy Res. 2017. PMID: 28043062

5

Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.

Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jørgensen KN, Melle I, Andreassen OA, Molden E, Jönsson EG. Iversen TSJ, et al. Among authors: molden e. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:263-271. doi: 10.1016/j.pnpbp.2017.11.004. Epub 2017 Nov 7. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 29122637

6

Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients.

Smith RL, Tveito M, Kyllesø L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, Molden E. Smith RL, et al. Among authors: molden e. Eur Neuropsychopharmacol. 2020 Aug;37:64-69. doi: 10.1016/j.euroneuro.2020.06.007. Epub 2020 Jun 25. Eur Neuropsychopharmacol. 2020. PMID: 32595082 Clinical Trial.

7

Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.

Molden E, Lunde H, Lunder N, Refsum H. Molden E, et al. Ther Drug Monit. 2006 Dec;28(6):744-9. doi: 10.1097/01.ftd.0000249944.42859.bf. Ther Drug Monit. 2006. PMID: 17164689

8

Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.

Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Bakken GV, et al. Among authors: molden e. Ther Drug Monit. 2011 Apr;33(2):222-6. doi: 10.1097/FTD.0b013e31821160c4. Ther Drug Monit. 2011. PMID: 21383647

9

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E. Haslemo T, et al. Among authors: molden e. Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20. Clin Pharmacol Ther. 2012. PMID: 22713701

10

Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking.

Haslemo T, Olsen K, Lunde H, Molden E. Haslemo T, et al. Among authors: molden e. Ther Drug Monit. 2012 Oct;34(5):512-7. doi: 10.1097/FTD.0b013e3182693d2a. Ther Drug Monit. 2012. PMID: 22972535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

197 results

Search Page